T1	Participants 454 625	Forty-two patients with carcinoma in situ of the bladder were randomized to intravesical BCG (21 patients) or mitomycin C plus doxorubicin sequential therapy (21 patients)
T2	Participants 772 812	27 had grade 2 and 15 had grade 3 cancer
